UltraClear Cold-Laser Blepharoplasty — The 2910nm Fiber Laser Approach

What UltraClear actually is

The technology is sometimes called "cold laser" or "cold fiber laser," though the term is somewhat misleading — it still uses thermal energy. The accurate description: it uses much less thermal energy per unit of tissue effect than CO2 lasers, because the 2910 nm wavelength is more strongly absorbed by water (the main chromophore in skin) and therefore needs less energy to achieve the same surface effect.

Why the 2910 nm wavelength matters

Skin lasers work by depositing energy where it's absorbed. The absorption depends on the wavelength of the laser and the chromophore (the target molecule) in skin. For resurfacing lasers, the chromophore is water.

Comparing the three main ablative skin lasers:

UltraClear's advantage: at this wavelength, the device is highly tunable. It can be configured to mimic CO2's tightening effect when needed (deeper thermal coagulation) or to behave more like Er:YAG when minimal thermal damage is wanted (gentler resurfacing with less downtime).

Why this matters for upper-eyelid treatment

The upper eyelid is one of the more challenging zones for any energy-based device:

• Thinnest skin on the body — aggressive lasers risk burn-through or hypopigmentation
• Highly vascular and proximate to the eye — ocular safety is non-negotiable
• Patient downtime tolerance is often low — this is a visible area; patients can't easily "hide" recovery
• The eyelid skin is on the move — recovery is disrupted by routine eye opening/closing

UltraClear's lower thermal damage and faster recovery profile match these constraints well. Where CO2 might require 5–10 days of significant downtime in the upper-lid area, UltraClear can produce comparable tightening with 2–5 days of downtime. That's not a marginal improvement — it's a meaningful difference in patient experience.

UltraClear vs CO2 vs Morpheus 8

Who's an ideal UltraClear candidate

• Mild-to-moderate dermatochalasis — in the range where CO2 would work, but the patient wants less downtime
• Patients with darker skin types — lower risk of post-inflammatory hyperpigmentation
• Patients who can't tolerate the CO2 recovery — professional commitments, social schedule, intolerance to visible downtime
• Patients who want strong results in fewer sessions than Morpheus 8
• First-time energy-device patients who want a balanced risk-benefit

What a session looks like

1. Numbing — topical anesthesia 30–45 minutes before treatment
2. Eye protection — intraocular shields, same as CO2
3. Treatment — the laser scans the upper-lid skin in a fractional pattern; usually 10–15 minutes per eye area
4. Post-treatment care — cooling, occlusive ointment, sunglasses
5. Discharge — same day. Most patients are presentable for normal activities within 2–5 days.

Recovery details

Realistic results

UltraClear at moderate settings produces 30–50% improvement in mild-to-moderate dermatochalasis after one session — comparable to CO2 results. More aggressive settings approach CO2 outcomes for moderate cases.

Duration: 1–3 years before noticeable recurrence with mild treatment; longer with more aggressive sessions. Sun protection extends results meaningfully.

Risks and precautions

• Hyperpigmentation — lower risk than CO2 but not zero; particularly relevant in Fitzpatrick IV-VI
• Hypopigmentation — rare
• Prolonged redness — uncommon
• Infection — herpes simplex reactivation possible in patients with history; prophylaxis as needed
• Ocular injury — mitigated by shields and operator technique; same precautions as any periocular laser
• Insufficient response — if dermatochalasis is more severe than appearance suggested, results may be underwhelming; surgical referral is the alternative

When UltraClear is NOT the right answer

• Severe dermatochalasis — surgery still wins for significant skin excess
• Fat herniation — surgical only
• Brow ptosis — addresses the wrong layer
• True eyelid ptosis — lasers don't fix levator dysfunction
• Active eye disease or recent intraocular surgery — defer until cleared by ophthalmologist
• Pregnancy — elective; defer

When will UltraClear be available at La Clinica?

UltraClear is on our roadmap. Specific timing depends on equipment installation and training; we expect to add it to the laser offering in the coming months. This article exists now — in advance of the device arrival — both to help patients understand the technology and to make information available in Hebrew that doesn't yet exist online.

When the device is available, this page will be updated with a direct treatment-booking CTA. In the meantime: if you're interested in UltraClear and want to be notified when it's offered, or to discuss whether your case would be better served by CO2 or Morpheus 8 now versus waiting, a consultation is the next step.

The physics in more detail (for the technically curious)

Skin lasers are characterized by three interacting variables: wavelength (which chromophore is targeted), pulse duration (how long the energy is delivered), and fluence (energy per unit area). Each affects the clinical outcome differently.

For ablative skin lasers, the chromophore is intracellular water. The wavelength determines absorption coefficient — how strongly water absorbs that specific wavelength.

• 10,600 nm (CO2) has water absorption coefficient ~800 cm⁻¹. Decent absorption; significant penetration depth; substantial thermal spread to surrounding tissue.
• 2,940 nm (Er:YAG) has water absorption coefficient ~12,500 cm⁻¹ — the absorption peak for water. Almost all energy absorbed in the top layer; minimal thermal spread; aggressive surface ablation but limited dermal heating.
• 2,910 nm (UltraClear) has high water absorption (~10,000 cm⁻¹) similar to Er:YAG, but with engineered pulse characteristics that allow tunable thermal effects: short pulses behave Er:YAG-like (clean ablation, minimal heat), longer pulses produce CO2-like thermal coagulation.

The clinical translation: UltraClear can be set to produce the "tight skin" outcome of CO2 (deeper thermal effect) without the broader thermal damage to surrounding tissue. The collateral damage zone shrinks; the clinical effect remains.

What the published evidence shows

UltraClear and similar 2910nm hybrid fiber lasers entered widespread clinical use around 2020. The evidence base is younger than CO2 (which has ~30 years of literature) but is growing rapidly. Key findings from peer-reviewed studies:

• Comparable tightening to CO2 at similar fluence settings (multiple comparative studies)
• Shorter post-treatment erythema — typically 2–5 days vs CO2's 7–14
• Lower rate of post-inflammatory hyperpigmentation, particularly in Fitzpatrick III–V
• Comparable patient satisfaction scores with significantly less reported downtime burden
• Lower rates of prolonged erythema (PIE) — a recognized CO2 complication

Limitations of the evidence base:

• Smaller sample sizes than CO2 studies (technology is newer)
• Follow-up periods generally 6–12 months — long-term (5+ year) data is still maturing
• Some early studies industry-sponsored — though independent replications now exist

Overall: the published evidence supports the proposed mechanism and clinical claims. The technology is no longer experimental.

How settings are chosen for the upper eyelid

UltraClear is highly tunable. For periocular work, the typical parameter approach:

• Fluence (energy density) — moderate setting (significantly lower than maximum), calibrated to the thin upper-lid skin
• Density (treated area fraction) — lower density (15–30%) for safety in this delicate zone; higher would risk excess inflammation
• Pulse profile — longer pulse for tightening-oriented treatment vs shorter pulse for surface-resurfacing-oriented treatment
• Depth — controlled to penetrate through the epidermis into the upper dermis, but not deeper than necessary in this thin-skinned zone

Periocular settings are intentionally more conservative than settings used for, say, the chin or jawline — the thin upper-lid skin doesn't need (and shouldn't receive) maximum-intensity treatment.

UltraClear vs other ablative laser systems

For context, several manufacturers produce ablative or hybrid fractional laser systems used in aesthetic dermatology:

• Lumenis AcuPulse / UltraPulse — CO2 systems, the legacy gold standard. Well-established but the older thermal damage profile.
• Lutronic eCO2 / Action II — CO2 systems with refined fractional handpieces.
• Sciton ProFractional / JOULE Halo — hybrid systems with Er:YAG component.
• UltraClear (Acclaro Medical / Bridge Medical — system varies by region) — the 2910nm fiber-laser approach.

The mechanistic distinction between "CO2 family" and "fiber-laser/Er:YAG family" is more important than the brand: 10,600 nm wavelength produces more thermal damage; 2940/2910 nm wavelengths produce less thermal damage with comparable ablation. Manufacturers within each category compete on handpiece design, control software, and supplementary features. From a patient's standpoint, the family matters more than the brand.

Further reading

FAQ